Quviviq
(Daridorexant)ApprovedSmall molecule
Idorsia Pharmaceuticals Ltd.Daridorexant is used to help people who have trouble falling asleep or staying asleep. It works by blocking a chemical in the brain that promotes wakefulness, allowing people to sleep better.[2] Quviviq is currently approved and in use across 13 indications[4].[1]
Quviviq is one of 381 small molecule programs targeting Delirium. It is currently in Approved.
13
Indications
29
Total Trials
12
Active Trials
380
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
120 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Quviviq
Idorsia Pharmaceuticals Ltd.Approved
EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Lunsekimig
SanofiPhase 3
Tozorakimab
AstraZenecaPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Astegolimab
RochePhase 3
Titrated Oxygen
RRigshospitalet, Denmark
Phase 3
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Insomnia6 trials
Show 3 more trials
Alzheimer disease2 trials
Daridorexant for Alzheimer Disease Prevention
Recruiting·—·Phase 2·NCT07213349·240 enrolled
Delirium2 trials
Pregnancy2 trials
Midazolam1 trial
15 more indications
Statin1 trial
Single Dose1 trial
Efficacy and Safety1 trial
Menopause1 trial
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
Recruiting·—·Phase 4·NCT07136415·1,000 enrolled
Phase 11 trial
TED1 trial
Elderly1 trial
Sleep1 trial
Insomnia Disorders1 trial
Alcohol Use Disorder1 trial
Regulatory
FDA Approval Timeline[5]
Apr 7, 2022
QUVIVIQ
NDA NDA214985
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Quviviq drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Daridorexant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Orexin Receptor 2 Antagonist; Orexin Receptor Antagonist; Orexin Receptor 1 Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company